Rat Branched Chain Alpha-Ketoacid Dehydrogenase Kinase (BCKDK) CLIA Kit

Product specifications

CLIA Kits

Branched Chain Alpha-Ketoacid Dehydrogenase Kinase (BCKDK)

Rat

Chemiluminescent

Quantitative

Sandwich

3.12 ng/ml - 200 ng/ml

< 1.29 ng/ml

Optimal dilutions/concentrations should be determined by the end user.

96 tests

5 × 96 tests

10 × 96 tests

Lyophilized

CLIA

Tissue homogenates, cell lysates and other biological fluids.

Shipped within 5-20 working days.

 Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual.

No

BCKDKD,BCKDH kinase 1,BCKDHKIN,BDK

CLIA Kits BCKDK

RUO

The validity for this kit is at least 6 months. Up to 12 months validity can be provided on request.   This product is for research use only.   The range and sensitivity is subject to change. Please contact us for the latest product information. For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments.   Please note that our ELISA and CLIA kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein.

Descripción

Branched Chain Keto Acid Dehydrogenase Kinase (BCKDK) is a pivotal regulatory enzyme in the catabolism of branched-chain amino acids (BCAAs), including leucine, isoleucine, and valine, which are essential amino acids important for protein synthesis, energy production, and metabolic signaling. BCKDK functions by phosphorylating and inhibiting the activity of the branched-chain α-keto acid dehydrogenase (BCKD) complex, a key enzymatic complex responsible for the oxidative decarboxylation of branched-chain α-keto acids derived from BCAAs. This regulatory action of BCKDK prevents excessive degradation of BCAAs and maintains metabolic balance, particularly under conditions requiring the conservation of these amino acids. Dysregulation of BCKDK activity has been implicated in metabolic disorders such as maple syrup urine disease (MSUD), characterized by the accumulation of toxic levels of BCAAs and their corresponding keto acids. Additionally, mutations in the BCKDK gene have been linked to neurodevelopmental disorders and autism spectrum disorders due to altered amino acid metabolism. Given its critical role in amino acid homeostasis and metabolic signaling, BCKDK is a potential therapeutic target for treating metabolic diseases and conditions associated with BCAA dysregulation.

Related Products

Rat Bckdk ([3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial) ELISA Kit

Ver Producto

Branched Chain Alpha-Ketoacid Dehydrogenase Kinase (BCKDK) Antibody

BCKDK Antibody is a Rabbit Polyclonal Antibody against BCKDK.

Ver Producto

Branched Chain Alpha-Ketoacid Dehydrogenase Kinase (Bckdk) Antibody

Catalyzes the phosphorylation and inactivation of the branched-chain alpha-ketoacid dehydrogenase complex, the key regulatory enzyme of the valine, leucine and isoleucine catabolic pathways. Key enzyme that regulate the activity state of the BCKD complex (By similarity).

Ver Producto